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bstract
ationale  and  objectives:  To assess if ferumoxtran-10 (f-10) improves accuracy of MRI to detect lymph node (LN) metastasis in advanced cervical
ancer.
aterials  and  methods:  F-10 MRI component of an IRB approved HIPAA compliant ACRIN/GOG trial was analyzed.
Patients underwent f-10 MRI followed by extra-peritoneal or laparoscopic pelvic and abdominal lymphadenectomy. F-10-sensitive sequences
ere T2* GRE sequences with TE of 12 and 21. Seven independent blinded readers reviewed f-10-insensitive sequences and all sequences in
ifferent sessions. Region correlations were performed between pathology and MRI for eight abdomen and pelvis regions. Sensitivity and specificity
ere calculated at participant level. Reference standard is based on pathology result of surgically removed LNs.
esults:  Among 43 women enrolled in the trial between September 2007 and November 2009, 33 women (mean age 49 ±  11 years old) with
dvanced cervical cancer (12 IB2, 3 IIA, 15 IIB and 3 IIIB, 29 squamous cell carcinomas, 32 grade 2 or 3) were evaluable. Based on histopathology,
N metastasis was 39% in abdomen and 70% in pelvis. Sensitivity of all sequence review in pelvis, abdomen, and combined were 83%, 60%, and
6%, compared with 78%, 54%, and 80% for f-10 insensitive sequences (P: 0.24, 0.44 and 0.14, respectively). Mean diameter of the largest positive
ocus on histopathology was 13.7 mm in abdomen and 18.8 mm in pelvis (P  = 0.018). Specificities of all sequence review in pelvis, abdomen, and
ombined were 48%, 75%, and 43%, compared with 75%, 83%, and 73% (P: 0.003, 0.14, 0.002 respectively) for f-10 insensitive sequences.
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onclusion:  Addition of f-10 increased MRI sensitivity to detect LN metastasis in advanced cervical cancer. Increased sensitivity did not reach
tatistical significance and was at the expense of lower specificity.
 2014 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
y-nc-nd/4.0/).
n-10
a
o
w
s
2
2
w
m
p
T
i
n
o
a
(
i
p
I
I
e
o
r
w
2
r
r
a
M
t
i
i
o
c
c
w
p
seywords: Cervical cancer; Lymph node metastasis; MRI; USPIO; Ferumoxtra
.  Introduction
Nonsurgical therapy fails to control loc-oregional disease in
0–85% of patients with locally advanced cervical carcinoma
1–6]. This may be due to understaging clinically [7]. In many
nstances, errors in staging are related to undiagnosed lymph
ode (LN) metastases [8,9]. In a recent meta-analysis, positive
redictive value (PPV) of CT was 60% and the negative pre-
ictive value (NPV) was 91% for detection of retroperitoneal
ymph node metastasis with no significant difference between
RI and CT accuracy [10].
It is suggested that accuracy of MRI is improved by using
erumoxtran-10 (f-10) nanoparticles. f-10, an ultra-small parti-
le iron oxide (USPIO) agent, is the most widely investigated
ontrast medium in clinical trials. It has been used in a num-
er of malignancies, including breast [11], lung [12], head and
eck [13,14], and abdominal and pelvic malignancies [15,16].
n a recent study Rockall et al. [17] evaluated 44 women with
ndometrial (n  = 15) and cervical (n  = 29) cancer with f-10, sen-
itivity of f-10 MRI was significantly higher than size criteria
or one reviewer (P  = 0.031) and showed a trend in the other
eviewer (P  = 0.06) without compromise of specificity.
This prospective multicenter clinical trial conducted by
CRIN (American College of Radiology Imaging Network) and
OG (Gynecology Oncology Group) was designed to evalu-
te the efficacy of PET/CT and f-10 MRI in the evaluation of
N metastasis in women with advanced cervical cancer. Since
he provider of Combidex decided to discontinue further pro-
uction, MRI component of the trial was closed. We report the
esults of the MRI component here. Our hypothesis was that f-10
mproves accuracy of standard MRI (without USPIO agent) to
etect LN metastasis in women with loco-regionally advanced
ervical cancer.
.  Materials  and  methods
.1.  Study  population
This is an IRB approved HIPAA compliant non-randomized
rospective multicenter trial conducted by ACRIN/GOG. All
atients provided written consent to participate in the study. Trial
as IRB approved at all centers.
Patients were included who had primary, previously
ntreated, histologically confirmed, loco-regionally advanced
stages IB2, IIA2, IIB-IVA based on clinical examina-
ion ±  imaging), invasive carcinoma of the cervix and were
ppropriate surgical candidate to undergo extra-peritoneal or
aparoscopic pelvic and abdominal LN sampling within 2 weeks
fter MRI. Patients who had metastasis outside of the pelvis or
r
w
cbdominal LNs, prior pelvic radiation therapy or prior pelvic
r abdominal lymphadenectomy, other invasive malignancies
ithin the last 5 years, with the exception of non-melanoma
kin cancer, and patients who had received ferumoxides within
 weeks of enrollment were excluded.
.2.  Imaging  protocol
Trial schema is shown in Fig. 1. All analyzed patients under-
ent MRI followed by surgery within 2 weeks of MRI.
Patients underwent a single MRI, performed on a 1.5 T
agnet with pelvic phased-array coil extending from pubic sym-
hysis to the level of the origin of the inferior mesenteric artery.
he MR sequences consisted of axial T1 GRE, axial and sag-
ttal FSE, and axial T2* GRE. Slice thickness was 3 mm and
o gap for all sequences. T2* sequences were obtained at TE
f 12 and 21. MRIs were acquired 24–36 h after intravenous
dministration of f-10. Patients received 2.6 mg/kg of f-10
Combidex; AMAG pharmaceuticals, Lexington, MA) diluted
n 100 ml of normal saline and infused over 30 min. F-10 was
rovided as an IND (investigational new drug) agent by AMAG
nc (Cambridge, MA). IND was held by the National Cancer
nstitute. The use of anti-peristaltic glucagon, 1 mg IM was
ncouraged and 20/33 (61%) received glucagon. We obtained
nly a post f-10MRI since it has been validated that trained
eviewers would perform equally well reviewing post-f-10 MRI
ithout access to pre-f-10 MRI [18].
.3.  Surgery
Surgery consisted of lymphadenectomy in eight nodal
egions: right and left obturator, right and left external iliac,
ight and left common iliac, and right para-caval and aorto-caval
nd left para-aortic. Each was compared separately between
RI and lymphadenectomy results. Surgeons were expected
o provide a full lymphadenectomy for each of the eight regions
ndependently or confirm malignancy by intra-operative biopsy,
f a region was not resectable. Combined external iliac and
bturator LN sub-regions were considered pelvic region and
ombined common iliac and para-aortic LN sub-regions were
onsidered abdominal region for statistical analysis. A patient
as considered to have pelvic or abdominal malignant lym-
hadenopathy if there was at least one of the included 4
ub-regions involved.Surgeons were not blinded to the pre-enrollment imaging
esults. Protocol required discussion of the result of f-10 MRI
ith the surgeons. However, we could not confirm if this dis-
ussion occurred.
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Fig. 1. Study schema.
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p.4.  Pathology  analysis
Pathology review was performed at each institution. For
Ns smaller than 10 mm in long axis, they were bisected
nto two halves, each approximately 5 mm thick. For LNs
onger than 10 mm, the nodes were sectioned at 5 mm inter-
als parallel to the short axis, and one slide was prepared
rom each section. The following data were collected: total
umber of LNs per sub-region, presence/absence of LN
etastasis, size of the largest focus of metastasis per sub-
egion, size of the largest positive and negative LN per
ub-region.
a
n
v.5.  Imaging  review
The initial design of the study required review by seven
eviewers based on sample size calculation. Four of the seven
eaders had previous experience in review of f-10 trials and
he other three went through an initial didactic training as
ell as three test cases before reviewing study MRIs. Test
ases were not selected from study cases. The readers inde-
endently reviewed MRIs, blinded to the clinical information
nd final pathology results. They were chosen from centers
ot involved in the accrual of patients. Readers were pro-
ided MRI images either at the ACRIN headquarters or in
14 M. Atri et al. / European Journal of R
Fig. 2. (A) Axial T1W (TR 175, TE 1.9), and B) axial T2* (TR 2200, TE 21) in
a 34 year-old woman with squamous carcinoma of the cervix. A right obturator
lymph node is present (arrows) measuring 10 mm × 10 mm that is hypo T1 signal
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of 12 patients with abdominal lymph node metastasis also hadA), and high T2* signal (B) indicating lack of accumulation of USPIO agent.
his was a true positive LN at pathology.
heir own institutions using different commercially available
amiliar workstation. Review process was arranged in two sett-
ngs; (a) first, all sequences excluding T2* GRE sequence were
eviewed (USPIO-insensitive sequences), (b) second, review of
ll sequences including USPIO-sensitive sequences. During the
rst review of each region, the number of positive and negative
Ns, presence/absence of metastatic LN, and short axis of the
argest positive/negative LNs was recorded. A LN was consid-
red positive if the short axis was >8 mm for a node with short
xis > half the length of long axis, and >10 mm for a node with
hort axis < half the length of long axis in all regions. Previously
ublished criteria were used for evaluation of USPIO-sensitive
equences [18]. High intensity LN or high intensity focus in an
therwise normal intensity LN on T2* was considered positive
Fig. 2).
The LNs were rated from 1 to 6 to capture the possibil-
ty of malignancy, with 1 = definitely benign, 2 = most likely
enign, 3 = probably benign, 4 = probably malignant, 5 = most
ikely malignant and 6 = definitely malignant. For the purpose
f sensitivity and specificity calculation, 1–3 was considered
egative and 4–6 was considered positive.
.6.  Data  analysis
The primary unit of analysis was patient and not nodal region.
athology data was the reference standard. The abdomen or
elvis region was considered positive if at least one of the cor-
esponding four sub-regions had a positive reference standard.
owever, if any sub-regional reference standard was missing,
p
f
(adiology Open 2 (2015) 11–18
nd the rest of the sub-regions were negative, the reference
tandard for abdomen or pelvis was considered missing.
In order for the reader to get credit for making a correct
iagnosis, the true positive node should be on the same side
s identified by the imaging, i.e. para-aortic or common iliac
or abdomen region, and external iliac or obturator for pelvic
egion. For the calculation of sensitivity, specificity, NPV, PPV,
nd AUC, the individual reader scores were used.
For each reader, 95% CIs for the estimates of sensitivity,
pecificity, PPV and NPV were presented as the exact confi-
ence intervals (Clopper-Pearson). 95% CIs for the differences
n sensitivity and specificity were calculated using the method
y Fleiss [19]. P-values for the sensitivity and specificity com-
arisons were based on McNemar’s test statistic. Comparison
f PPVs and NPVs were based on a GEE model proposed by
eisenring et al. [20], where the link function was chosen to be
he logit function, hence the inference was made on the odds
atio of PPV or NPV and P-values were derived from Wald’s
tatistic. Estimates, 95% CIs and P-values related to AUC were
erived by using the Delong & Delong method [21] for empirical
OC curve.
Comparison of the average sensitivity/specificity, PPV, and
PV between USPIO-insensitive sequences and all sequences,
or an average reader, were computed with a generalized linear
ixed model with a random reader effect. The comparison of
verage empirical AUCs between USPIO-insensitive sequences
nd all sequences, from all seven readers, were computed
sing Obuchowski’s method [22]. MRI diagnoses of LN metas-
asis (yes/no) from the seven readers were compared with
appa statistics, assuming all observations are independent, for
SPIO-insensitive sequences and all sequences, and for abdom-
nal, pelvic, and combined. The sensitivities or specificities
etween the seven readers were compared with generalized esti-
ating equation methodology.
.  Results
Forty-three women were accrued to the trial between
eptember 2007 and November 2009 at seven centers. Of those,
3 had undergone both MRI and surgery and were evaluable.
he other 10 patients were excluded because of the following
easons: patient refusing MRI (n  = 5), and no surgery due to the
xtent of disease (n  = 5). The 33 evaluable patients have mean
ge 49 ± 11 years. The stage distribution is 12 IB2, 3 IIA, 15
IB, and 3 IIIB. The tumor types are 29 squamous cell carci-
oma, 3 adenocarcinoma, and 1 embryonal rhabdomyosarcoma.
here are 1 grade 1, 20 grade 2, and 12 grade 3 tumors. The
ean primary tumor size is 5.4 ±  1.5 cm (median 5.6 cm, range
.9–8.0 cm) as measured on MRI.
Of the 33 patients, 31 had complete information for abdom-
nal lymph nodes based on pathology, and 12 were positive
prevalence 39%). Thirty patients had complete information for
elvic lymph nodes, and 21 were positive (prevalence 70%). Tenelvic metastasis. Range and mean size of the largest metastatic
ocus in the LN on pathology in the abdomen were 1–30 mm
mean 13.7 ±  10 mm) and in the pelvis were 2–50 mm (mean
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8.8 ±  11.7 mm). The largest focus of metastasis in a LN was
arger in the pelvis than those in the abdomen (P  = 0.018).
The sensitivities of f-10 MRI all sequences to detect LN
etastasis were 83% in pelvis, 60% in abdomen, and 86%
bdomen and pelvis combined, compared with 78%, 54%, and
0% respectively for USPIO-insensitive sequences. Although
he sensitivities of f-10 MRI all sequences were higher than the
nes from USPIO-insensitive sequences for all three compar-
sons, the differences were not statistically significant (P  = 0.24,
.44 and 0.14, respectively) (Table 1).
The specificities of f-10 MRI all sequences were 48%
n pelvis, 75% in abdomen, and 43% abdomen and pelvis
ombined, compared with 75%, 83%, and 73% for USPIO-
nsensitive sequences. Although the specificities of f-10
RI all sequences were lower than the ones from USPIO-
nsensitive sequences for all three comparisons, the differences
ere significant in the pelvis (P  = 0.003) and combined
bdomen/pelvis (P  = 0.002) but not in the abdomen alone
P = 0.14).
To determine the effect of LN size on the accuracy values of f-
0, we compared the accuracy values for LN metastasis detection
or LNs > 8 mm in short axis and those ≤  8 mm (Table 2). Eight
illimeter was used as a threshold since this is the value we used
o consider a LN abnormal on USPIO-insensitive sequences.
N size on USPIO-insensitive sequences were used to do this
nalysis. Among patients with LNs ≤  8 mm (which, by defini-
ion, were negative on USPIO-insensitive sequences), f-10 MRI
ncreased sensitivity of MRI from 0% to 18% (P  = 0.018) in the
bdomen and from 9% to 36% (P  = 0.011) in the pelvis but this
as at the expense of reduced specificity. Among patients with
Ns > 8 mm, the addition of f-10 MRI did not improve sensitivity
ver USPIO-insensitive sequences alone.
c
[
i
f
able 1
ccuracy values comparing average results of the 7 readers for all sequences and US
All sequence 
Est 95% CI Range 
bdomen
ensitivity 0.60 (0.49, 0.70) 0.50–0.75 
pecificity 0.75 (0.67, 0.82) 0.58–0.89 
UC 0.69 (0.52, 0.85) 0.62–0.75 
PV 0.60 (0.49, 0.70) 0.47–0.75 
PV 0.75 (0.67, 0.81) 0.69–0.83 
ccuracy 0.69 (0.63, 0.75) 0.58–0.77 
elvis
ensitivity 0.83 (0.76, 0.88) 0.71–0.90 
pecificity 0.48 (0.35, 0.61) 0.22–0.67 
UC 0.73 (0.58, 0.88) 0.58–0.85 
PV 0.79 (0.72, 0.84) 0.68–0.85 
PV 0.55 (0.41, 0.67) 0.25–0.67 
ccuracy 0.72 (0.66, 0.78) 0.57–0.77 
ombined
ensitivity 0.86 (0.79, 0.90) 0.78–0.96 
pecificity 0.43 (0.30, 0.56) 0.25–0.63 
UC 0.71 (0.54, 0.88) 0.62–0.84 
PV 0.81 (0.75, 0.86) 0.75–0.87 
PV 0.51 (0.37, 0.65) 0.29–0.67 
ccuracy 0.75 (0.68, 0.80) 0.65–0.81 adiology Open 2 (2015) 11–18 15
The areas under the ROC curve (AUC) for both sets of
equences review were almost identical, with AUC of 0.69 in the
bdomen for both sets of sequences. AUC was 0.78 for USPIO-
nsensitive sequences and 0.75 for all sequences review in the
elvis (P  = 0.47) (Table 1).
Table 3 shows inter-reader agreement on lymph node metas-
asis diagnosis for all regions. The inter-reader agreement to
dentify a LN as positive or negative was good to excellent
Kappa: 0.74–0.89) for USPIO-insensitive sequences that relied
n size criteria alone. The agreement was moderate (Kappa:
.46–0.54) for all sequences. The sensitivity and specificity val-
es for each individual reader in any of the regions did not differ
ignificantly (P  > 0.32).
.  Discussion
The purpose of this trial was to determine the accuracy of
-10 MRI in the detection of LN metastasis in loco-regionally
dvanced cervical cancer. The knowledge of the extent of LN
etastasis is important to determine the radiation field in those
atients who undergo primary chemo-radiotherapy or postop-
rative adjuvant radiotherapy.
The prevalence of LN metastasis in this cohort was 70% in the
elvis and 39% in the abdomen with two patients with abdominal
N metastasis only. This corresponds to the known sequential
N metastasis in cervix cancer with pelvic LN metastastases
enerally occurring first, followed by common iliac and abdom-
nal LN metastasis [23]. The prevalence of LN metastasis in our
ohort is higher than that previously reported in the literature
23,24]. This may potentially be related to a number of factors,
ncluding more complete surgical lymphadenectomy being per-
ormed on this prospective evaluation with a defined surgical
PIO-insensitive sequences. Est.: Estimate.
USPIO-insensitive sequence P-value
Est 95% CI Range
0.54 (0.43, 0.64) 0.50–0.58 0.438
0.83 (0.75, 0.88) 0.68–0.89 0.136
0.69 (0.52, 0.85) 0.62–0.73 0.926
0.66 (0.54, 0.76) 0.54–0.75 0.454
0.74 (0.66, 0.80) 0.70–0.76 0.878
0.71 (0.65, 0.77) 0.65–0.74 0.600
0.78 (0.70, 0.84) 0.76–0.81 0.243
0.75 (0.62, 0.84) 0.56–0.89 0.003
0.75 (0.60, 0.89) 0.73–0.85 0.726
0.88 (0.81, 0.92) 0.80–0.94 0.049
0.59 (0.48, 0.69) 0.50–0.64 0.629
0.77 (0.70, 0.82) 0.70–0.80 0.315
0.80 (0.73, 0.85) 0.78–0.83 0.144
0.73 (0.60, 0.83) 0.63–0.88 0.002
0.74 (0.57, 0.91) 0.73–0.82 0.435
0.90 (0.83, 0.94) 0.86–0.95 0.043
0.55 (0.44, 0.66) 0.50–0.60 0.642
0.78 (0.72, 0.83) 0.74–0.81 0.430
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Table 2
Accuracy values comparing average results of the seven readers for all sequences and USPIO-insensitive sequences for nodes with longest short axis above and
below 8 mm as determined by MRI.
All sequences USPIO-insensitive sequences P-value
Est 95% CI Est 95% CI
Abdomen
≤8 mm Sensitivity 0.18 (0.06, 0.44) 0.00 0.018
Specificity 0.85 (0.74, 0.92) 0.97 (0.91, 0.99) 0.004
>8 mm Sensitivity 0.93 (0.81, 0.98) 0.98 (0.86, 1) 0.333
Specificity 0.23 (0.06, 0.61) 0.07 (0.01, 0.41) 0.133
Pelvis
≤8 mm Sensitivity 0.36 (0.19, 0.58) 0.09 (0.03, 0.27) 0.011
Specificity 0.56 (0.4, 0.71) 0.92 (0.8, 0.97) <0.001
>8 mm Sensitivity 0.98 (0.93, 1) 1.00 0.998
Specificity 0.15 (0.03, 0.48) 0.08 (0.01, 0.43) 0.554
Table 3
Agreement of readers on positive/negative diagnosis at the region level. Kappa statistics was used for inter-observer agreement. Kappa values ≤0 is poor, 0–0.2 is
slight, 0.2–0.4 is fair, 0.4–0.6 is moderate, 0.6–0.8 is substantial, 0.8–1 is almost perfect.
Comparison of all readers All sequence USPIO-insensitive sequences
Kappa Standard error P-value Kappa Standard error P-value
Region
Abdomen 0.54 0.04 <0.001 0.74 0.04 <0.001
P <0.001 0.84 0.04 <0.001
C <0.001 0.89 0.04 <0.001
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Fig. 3. (A) Axial T2W (TR 5500, TE), and B) axial T2* (84 TR 2200, TE
21) in a 17 year-old-woman with squamous carcinoma of the cervix. A lymph
node is present posterior to the right common iliac artery (arrows) measuringelvis 0.52 0.04 
ombined 0.46 0.04 
ndpoint, or selection bias on the part of the surgeons if they
ad access to pre-enrollment imaging.
The sensitivity of all sequences was higher than USPIO-
nsensitive sequences in both abdomen and pelvis, but without
tatistical significance. Due to the moderate size of the study
opulation, this study may lack sufficient power to detect a true
mprovement of diagnostic sensitivity with f-10 MRI compared
ith an MRI without f-10. F-10 increases sensitivity of MRI sig-
ificantly to detect LN metastasis in LNs with short axis ≤  8 mm
n both the abdomen and the pelvis but this was at the expense of
educed specificity. Improving sensitivity is in agreement with
ther studies and a recent meta-analysis of the utility of f-10
RI in different cancers [25].
The mean diameter of the largest positive focus in the LNs
f abdomen was significantly smaller than in the pelvis. The
ensitivity of both sets of sequences was lower in the abdomen,
ikely due to the smaller size of metastatic foci in the abdomi-
al LNs. The specificities of USPIO-insensitive sequences were
ignificantly higher than those of all sequences in the pelvis and
ombined abdomen/pelvis but not in the abdomen.
It is difficult to explain the lower specificity of MRI consid-
ring we were not able to do node for node analysis in this
ulticenter trial. We speculate, however, that it could be partly
elated to lack of removal of some of the involved LNs on imag-
ng during lymphadenectomy. Fig. 3 is an example of an enlarged
ommon iliac LN that was positive on all sequence. This LN
egion was called negative on lymphadenectomy. Some regions
re likely more difficult to dissect, such as LNs posterior to
he common iliac vessels. In a multicenter study of f-10 MRI in
rostate cancer, a high percentage of positive lymph nodes could
10 mm × 15 mm that is intermediate T2 signal (A), and high T2* signal (B)
indicating lack of accumulation of USPIO agent. This was region was called
negative at pathology likely because of the location of this lymph node behind
the artery and not accessible to lymphadenectomy.
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e confirmed histologically only by extended lymphadenectomy
eyond the standard lymphadenectomy or MR or CT-guided
iopsy [26]. Similar results were obtained in another study eval-
ating diffusion-weighted MR imaging in normal sized lymph
odes in patients with bladder or prostate cancer using extended
elvic lymphadenectomy [27]. Another explanation would be
 true false positive by f-1–0 MRI. Many patients with cervi-
al cancer develop chronic infection within their primary tumor.
his could potentially result in reactively enlarged lymph nodes.
t is possible that reactive LNs caused apparent defects within
he nodes resulting in false positive diagnosis. In the multicen-
er trial on prostate cancer [26], 24% of positive LNs on f-10
RI did not show histological confirmation [26]. There is no
ther study that has evaluated the utility of f-10 MRI in this
ohort of patients. However, multicenter trials generally have
ess favorable results than the single center studies.
The inter-reader agreement to identify positive or negative
N was good to excellent for USPIO-insensitive sequences
hat relied on size criteria. The agreement was moderate for
equences relying on USPIO sensitive sequence. This is not
nexpected since this sequence is less robust to acquire and more
ifficult to interpret. The range of experience of the seven read-
rs in this study did not significantly influence their accuracy
alues (P  > 0.05).
This study has a number of limitations. The main limi-
ation is the small sample size due to stoppage of the trial
ecause of unavailability of Combidex. The second limitation
s that we were not able to do node for node comparison.
his is not feasible for most studies that compare imaging
ith lymphadenectomy, especially in a multicenter trial. New
D acquisitions with isotropic 1 mm slices could potentially
mprove results. Additionally, thinner than 5 mm pathol-
gy sections could have potentially detected smaller foci of
etastasis.
Ferumoxtran-10 has been discontinued but Combidex®
as been purchased by a Dutch university that intends
o launch global trials (www.prweb.com/releases/2013/4/
rweb10600077.htm).
In conclusion, in this study, the addition of USPIO agent adds
o the sensitivity of MRI to detect LN metastasis in advanced
ervical cancer. However, specificity was lower in the pelvis
hen USPIO MRI was considered. Both USPIO-insensitive and
ensitive sequences performed better in the pelvis as compared to
he abdomen. This appears to be due to larger foci of metastatic
isease in the lymph nodes in the pelvis. Further trial with a
arger sample size is warranted once a LN specific agent for
RI becomes available.
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